RheumaBlog

Same dragon, different day.

Carla's Corner

I’ve been seething since I read Prime Therapeutics’ October 17 news release asserting that patients are being prescribed biologics outside of American College of Rheumatology (ACR) guidelines. The referenced Prime Therapeutic reports assert that patients are being switched from conventional DMARDs to more-expensive biologic treatments before the DMARD therapy is given a proper chance to work (as much as 24 weeks – or almost six months). The report concludes this has caused an unwarranted higher total cost of care for RA patients. The conventional first-line DMARD is methotrexate (MTX) and the triple therapy of MTX/hydroxycholoquine/sulfasalazine was also discussed.

For those of you who are not familiar with Prime Therapeutics, they manage pharmacy benefits for health plans, employers, and government programs including Medicare and Medicaid. Their opinions affect more than 20 million people. For many, this is the entity that determines whether or not their prescribed medication treatments are approved and…

View original post 866 more words

Categories: RA

One thought on “I Disagree with Prime Therapeutics’ Reports That May Limit Access to Biologics and Here’s Why

  1. christa159 says:

    Great Points. Thanks for voicing counter arguments and being a patient advocate.

    Like

Comments are closed.

%d bloggers like this: